title: Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.
abstract: Management of patients who experience biochemical failure after radical radiotherapy with or without hormonal therapy is highly challenging. The clinician must not only choose the type of treatment, but also the timing and optimal sequence of treatment administration. When biochemical failure occurs, numerous treatment scenarios are possible, thus making it more difficult to select the optimal approach. Moreover, rapid and ongoing advances in treatment options require that physicians make decisions that could impact both survival and quality of life. The aim of the present consensus statement, developed by the Urological Tumour Working Group (URONCOR) of the Spanish Society of Radiation Oncology (SEOR), is to provide cancer specialists with the latest, evidence-based information needed to make the best decisions for the patient under all possible treatment scenarios. The structure of this consensus statement follows the typical development of disease progression after biochemical failure, with the most appropriate treatment recommendations given for each stage. The consensus statement is organized into three separate chapters, as follows: biochemical failure with or without local recurrence and/or metastasis; progression after salvage therapy; and treatment of castration-resistant patients.
authors.affiliation: Servicio Oncología Radioterápica-ERESA, Hospital General Universitario, Valencia, Spain.
authors.forename: José
authors.initials: J
authors.lastname: López Torrecilla
authors.affiliation: Radiation Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
authors.forename: Asunción
authors.initials: A
authors.lastname: Hervás
authors.affiliation: Radiation Oncology Department, Hospital Universitario de la Princesa, Madrid, Spain.
authors.forename: Almudena
authors.initials: A
authors.lastname: Zapatero
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Gómez Caamaño
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Universitario de Salamanca, Valencia, Spain.
authors.forename: Victor
authors.initials: V
authors.lastname: Macías
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
authors.forename: Ismael
authors.initials: I
authors.lastname: Herruzo
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: Xavier
authors.initials: X
authors.lastname: Maldonado
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Gómez Iturriaga
authors.affiliation: Servicio Oncología Radioterápica, Hospital Clinic, Barcelona, Spain.
authors.forename: Francesc
authors.initials: F
authors.lastname: Casas
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Universitario Gregorio Marañón, Madrid, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: González San Segundo
keywords: Biochemical failure; Castration-resistant prostate cancer; Hormone therapy; PSA; Prostate cancer; Radiotherapy